BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huiskamp LFJ, Chargi N, Devriese LA, de Jong PA, de Bree R. The predictive and prognostic value of low skeletal muscle mass for dose-limiting toxicity and survival in head and neck cancer patients receiving concomitant cetuximab and radiotherapy. Eur Arch Otorhinolaryngol 2020;277:2847-58. [PMID: 32335709 DOI: 10.1007/s00405-020-05972-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Casasayas M, García-Lorenzo J, Gómez-Ansón B, Medina V, Fernández A, Quer M, León X. Low skeletal muscle mass assessed directly from the 3rd cervical vertebra can predict pharyngocutaneous fistula risk after total laryngectomy in the male population. Eur Arch Otorhinolaryngol 2021. [PMID: 34665301 DOI: 10.1007/s00405-021-07127-3] [Reference Citation Analysis]
2 Huiskamp LFJ, Chargi N, Devriese LA, May AM, Huitema ADR, de Bree R. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis. J Clin Med 2020;9:E3780. [PMID: 33238530 DOI: 10.3390/jcm9113780] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Thureau S, Lebret L, Lequesne J, Cabourg M, Dandoy S, Gouley C, Lefebvre L, Mallet R, Mihailescu SD, Moldovan C, Rigal O, Veresezan O, Modzewelski R, Clatot F. Prospective Evaluation of Sarcopenia in Head and Neck Cancer Patients Treated with Radiotherapy or Radiochemotherapy. Cancers (Basel) 2021;13:753. [PMID: 33670339 DOI: 10.3390/cancers13040753] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Surov A, Wienke A. Low skeletal muscle mass predicts relevant clinical outcomes in head and neck squamous cell carcinoma. A meta analysis. Ther Adv Med Oncol 2021;13:17588359211008844. [PMID: 34035838 DOI: 10.1177/17588359211008844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Surov A, Pech M, Gessner D, Mikusko M, Fischer T, Alter M, Wienke A. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis. Clin Nutr 2021;40:5298-310. [PMID: 34536638 DOI: 10.1016/j.clnu.2021.08.023] [Reference Citation Analysis]
6 Vangelov B, Bauer J, Kotevski D, Smee RI. The use of alternate vertebral levels to L3 in computed tomography scans for skeletal muscle mass evaluation and sarcopenia assessment in patients with cancer: a systematic review. Br J Nutr 2021;:1-14. [PMID: 33910664 DOI: 10.1017/S0007114521001446] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Yunaiyama D, Okubo M, Arizono E, Tsukahara K, Tanigawa M, Nagao T, Saito K. Sarcopenia at the infrahyoid level as a prognostic factor in patients with advanced-stage non-virus-related head and neck carcinoma. Eur Arch Otorhinolaryngol 2021. [PMID: 34697649 DOI: 10.1007/s00405-021-07147-z] [Reference Citation Analysis]
8 Vangelov B, Bauer J, Moses D, Smee R. A prediction model for skeletal muscle evaluation and computed tomography-defined sarcopenia diagnosis in a predominantly overweight cohort of patients with head and neck cancer. Eur Arch Otorhinolaryngol 2022. [PMID: 35835910 DOI: 10.1007/s00405-022-07545-x] [Reference Citation Analysis]